Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Section on Pediatric Drug Disposition and Pharmacokinetics

Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny

Nicholas L. Giebel, Jeffrey D. Shadley, D. Gail McCarver, Kenneth Dorko, Roberto Gramignoli, Stephen C. Strom, Ke Yan, Pippa M. Simpson and Ronald N. Hines
Drug Metabolism and Disposition July 2016, 44 (7) 1027-1037; DOI: https://doi.org/10.1124/dmd.116.069344
Nicholas L. Giebel
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. Shadley
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Gail McCarver
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Dorko
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Gramignoli
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen C. Strom
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Yan
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pippa M. Simpson
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald N. Hines
Departments of Pediatrics and Pharmacology and Toxicology, Medical College of Wisconsin, and Children’s Research Institute, Children’s Hospital and Health Systems, Milwaukee, Wisconsin (N.L.G., J.D.S., D.G.M., K.Y., P.M.S., R.N.H.); and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (K.D., R.G., S.C.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Variability in drug-metabolizing enzyme developmental trajectories contributes to interindividual differences in susceptibility to chemical toxicity and adverse drug reactions, particularly in the first years of life. Factors linked to these interindividual differences are largely unknown, but molecular mechanisms regulating ontogeny are likely involved. To evaluate chromatin structure dynamics as a likely contributing mechanism, age-dependent changes in modified and variant histone occupancy were evaluated within known CYP3A4 and 3A7 regulatory domains. Chromatin immunoprecipitation using fetal or postnatal human hepatocyte chromatin pools followed by quantitative polymerase chain reaction DNA amplification was used to determine relative chromatin occupancy by modified and variant histones. Chromatin structure representing a poised transcriptional state (bivalent chromatin), indicated by the occupancy by modified histones associated with both active and repressed transcription, was observed for CYP3A4 and most 3A7 regulatory regions in both postnatal and fetal livers. However, the CYP3A4 regulatory regions had significantly greater occupancy by modified histones associated with repressed transcription in the fetal liver. Conversely, some modified histones associated with active transcription exhibited greater occupancy in the postnatal liver. CYP3A7 regulatory regions also had significantly greater occupancy by modified histones associated with repressed transcription in the fetus. The observed occupancy by modified histones is consistent with chromatin structural dynamics contributing to CYP3A4 ontogeny, although the data are less conclusive regarding CYP3A7. Interpretation of the latter data may be confounded by cell-type heterogeneity in the fetal liver.

Footnotes

    • Received January 5, 2016.
    • Accepted February 25, 2016.
  • ↵1 Current affiliation: Milwaukee, Wisconsin.

  • ↵2 Current affiliation: Department of Pediatrics Critical Care, University of Michigan Health System, Ann Arbor, Michigan.

  • ↵3 Cary, North Carolina.

  • ↵4 Samsara Sciences, San Diego, California.

  • ↵5 Department of Laboratory Medicine, Karolinska Institutet and Hospital, Stockholm, Sweden.

  • ↵6 U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Research Triangle Park, North Carolina

  • This work was supported in part by the National Institutes of Health [Grant GM081344] (R.N.H. and D.G.M.) and the Swedish Research Council, Ventenskaprådet and the Torsten och Ragnar Söderberg Stiftelse (R.G. and S.C.S.).

  • dx.doi.org/10.1124/dmd.116.069344.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 44 (7)
Drug Metabolism and Disposition
Vol. 44, Issue 7
1 Jul 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on Pediatric Drug Disposition and Pharmacokinetics

Chromatin Structural Changes Regulating Human CYP3A Ontogeny

Nicholas L. Giebel, Jeffrey D. Shadley, D. Gail McCarver, Kenneth Dorko, Roberto Gramignoli, Stephen C. Strom, Ke Yan, Pippa M. Simpson and Ronald N. Hines
Drug Metabolism and Disposition July 1, 2016, 44 (7) 1027-1037; DOI: https://doi.org/10.1124/dmd.116.069344

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on Pediatric Drug Disposition and Pharmacokinetics

Chromatin Structural Changes Regulating Human CYP3A Ontogeny

Nicholas L. Giebel, Jeffrey D. Shadley, D. Gail McCarver, Kenneth Dorko, Roberto Gramignoli, Stephen C. Strom, Ke Yan, Pippa M. Simpson and Ronald N. Hines
Drug Metabolism and Disposition July 1, 2016, 44 (7) 1027-1037; DOI: https://doi.org/10.1124/dmd.116.069344
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Predicting Stereoselective PK of Carvedilol–A PBPK Approach
  • Pharmacokinetics of Oral Topotecan in Very Young Children
  • Consequences of Age Variation in Hepatic Extraction Ratios
Show more Special Section on Pediatric Drug Disposition and Pharmacokinetics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics